HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study
In Southeast Asia, HIV-infected patients frequently die during TB treatment. Many physicians are reluctant to treat HIV-infected TB patients with anti-retroviral therapy (ART) andhave questions about the added value of opportunistic infection prophylaxis to ART, the optimum ART regimen, and the benefit of initiating ART early during TB treatment.
Methods: We conducted a multi-center observational study of HIV-infected patients newly diagnosed with TB in Thailand.
Clinical data was collected from the beginning to the end of TB treatment. We conducted multivariable proportional hazards analysis to identify factors associated with death.
Results: Of 667 HIV-infected TB patients enrolled, 450 (68%) were smear and/or culture positive. Death during TB treatment occurred in 112 (17%).
In proportional hazards analysis, factors strongly associated with reduced risk of death were ART use (Hazard Ratio [HR] 0.16; 95% confidence interval [CI] 0.07-0.36), fluconazole use (HR 0.34; CI 0.18-0.64), and co-trimoxazole use (HR 0.41; CI 0.20-0.83). Among 126 patients that initiated ART after TB diagnosis, the risk of death increased the longer that ART was delayed during TB treatment.
Efavirenz- and nevirapine-containing ART regimens were associated with similar rates of adverse events and death.
Conclusions: Among HIV-infected patients living in Thailand, the single most important determinant of survival during TB treatment was use of ART. Controlled clinical trials are needed to confirm our findings that early ART initiation improves survival and that the choice of non-nucleoside reverse transcriptase inhibitor does not.
Author: Jay K Varma, Sriprapa Nateniyom, Somsak Akksilp, Wiroj Mankattitham, Chawin Sirinak, Wanchai Sattayawuthipong, Channawong Burapat, Wanitchaya Kittikraisak, Patama Monkongdee, Kevin P Cain, Charles D Wells and Jordan W Tappero
Credits/Source: BM
Published on: 2009-04-13
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
